Post a Free Blog

Submit A Press Release

Thursday, March 28, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeBusinessCan CVS Health Buy BioPharmX Corporation?

Can CVS Health Buy BioPharmX Corporation?

U.S.-stocks-ignoring-logic

Can CVS Health Buy BioPharmX Corporation? – CWEB.com

  • Corporate health-care deal value surged 37 percent last year, according to a new report  from consulting firm Bain & Company.
  • The number of health-care mergers and acquisitions rose 16 percent.
  • CVS Health’s planned acquisition of health insurer Aetna was the largest corporate deal of 2017 at $69 billion.

The health-care shopping spree isn’t likely to stop anytime soon.

Corporate deal value surged to $332 billion last year, up 27 percent from $261 billion in 2016, though still below the peak of $432 billion in 2015, according to a  new report  from consulting firm Bain & Company.

What does make BioPharmX unique?

  1. Financial Health: Does it have a healthy balance sheet?
  2. Management:Have insiders been ramping up their shares to take advantage of the market’s sentiment for BPMX’s future outlook?
  3. Other High-Growth Alternatives: BPMX is a high-growth stock you could be holding?

Walgreens  was also reportedly considering acquiring the part of drug distributor  AmerisourceBergen  that it doesn’t already own earlier this year, though  talks  have cooled.  Walmart  and health insurer  Humana  are having  early-stage talks  about strengthening their existing partnership, people familiar with the matter told CNBC.

BioPharmX Corporation  (BPMX) products are sold in CVS Health Pharmacy (NYSE:CVS),

Walgreens, Drugstore.com, GNC (NYSE:GNC), The Vitamin Shoppe, Harris Teeter and many more.

BioPharmX added 3,025 GNC store locations supplying Violet ® iodine, raising its
U.S. retail footprint to more than 7,500 stores. Availability of Violet iodine at GNC is expected to begin in
mid-December. GNC is a leading global specialty retailer of health and wellness products and is devoted to helping its
customers improve the quality of their lives. We believe the addition of GNC stores will accelerate VI2OLET revenue growth in the coming quarters.

Institutional investors currently hold major shares in  BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018

Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
VIVO CAPITAL, LLC 05/13/2018 16,128,515 2,328,571 16.87 3,306
FRANKLIN RESOURCES INC 05/13/2018 9,749,615 0 0.00 1,999
VANGUARD GROUP INC 05/13/2018 5,498,918 3,541,971 181.00 1,127
GEODE CAPITAL MANAGEMENT, LLC 03/31/2018 671,686 347,719 107.33 138
VIRTU FINANCIAL LLC 03/31/2018 426,837 426,837 New 88
BARCLAYS PLC 03/31/2018 362,900 362,900 New 74
SUSQUEHANNA INTERNATIONAL GROUP, LLP 03/31/2018 181,335 181,335 New 37
CITADEL ADVISORS LLC 03/31/2018 146,859 146,859 New 30
MCF ADVISORS LLC 03/31/2018 105,629 105,629 New 22
JANE STREET GROUP, LLC 03/31/2018 96,941 96,941 New 20
TWO SIGMA SECURITIES, LLC 03/31/2018 93,390 47,105 101.77 19
NORTHERN TRUST CORP 03/31/2018 92,518 0 0.00 19
UBS GROUP AG 03/31/2018 70,367 36,614 108.48 14
LADENBURG THALMANN FINANCIAL SERVICES INC. 03/31/2018 64,200 0 0.00 13
CREDIT SUISSE AG/ 03/31/2018 50,000 50,000 New 10
HOLDERS SHARES
Increased Positions 17 7,708,826
Held Positions 7 15,447,095
Total Institutional Shares 27 33,878,519

 Institutional Ownership

Institutions own approximately 19.42% of BioPharmX’ shares. Among active positions in the latest quarter, 7 holders increased their positions by a total of 10.8 million shares. This means there is a net increase in ownership of 9.61 million shares, which may suggest that institutions feel bullish about the stock.

 Cash as of March 9, 2018

  • Pro-forma cash of $14.2 million
    • $8.6 million as of January 31, 2018
    • $6.7 million in proceeds from warrant exercises after the end of the quarter

 Reverse Split

The company let an already approved reverse split expire.

“Regarding the expired reverse stock split, the company and its shareholders did not feel such an action would be in the best interest of the shareholders once the company was able to bring the company back into compliance with the NYSE American’s continued listing standards. The company is optimistic that it will be in compliance for continued listing standards regarding its share price by the June deadline.”

 

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that  BioPharmX Corporation  (BPMX)  , is undervalued.  

A potential Buy is very possible for  BioPharmX Corporation by a major Drug chain like CVS or Walgreens Pharmacy.

CWEB Analysts have Reiterate a Buy Rating for  BioPharmX Corporation  (BPMX)    and a Price Target of $7 within 12 months.

[youtube https://www.youtube.com/watch?v=9TXBP1t2rUc&w=560&h=315]

 

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more

Google code on Pinterest app suggests potential test of ad units, CWEB analysts say

Google and Pinterest might be testing a new partnership....

DraftKings Falls, NCAA Wants to Ban College Prop Bets. CWEB analysts issue Hold Rating on the stock.

Shares of DraftKings Inc.(DKNG) experienced a significant decline on...

Chick-Fil-A backtracks on NAE pledge, to use some antibiotics in chicken

Chick-Fil-A backtracked on its No Antibiotics Ever (NAE) policy...

Bloom Energy’s Price Target Cut at Susquehanna

Susquehanna analysts adjusted their price target for Bloom Energy...